Compare Heron Therapeutics Inc (HRTX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Under Armour Inc Class A — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Under Armour Inc Class A trades at $4.98 (market cap $2.07B). The key difference: Under Armour Inc Class A is far larger — about 30.4× Heron Therapeutics Inc's market cap, and Under Armour Inc Class A is more actively traded (12,050,442 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Under Armour Inc Class A for 99 Days on average.
| HRTX | UAA | |
|---|---|---|
Market Cap | $68.01M | $2.07B |
Volume | 1,891,941 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $8.14 |
52-Week Low | $0.27 | $4.17 |
Typical Hold Time | 35 Days | 99 Days |
Enterprise Value | $174.75M | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Under Armour (UAA) trades at $4.94, up 2.49% today, as the company navigates a challenging turnaround. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing, while technical indicators show a bullish trend despite negative profitability metrics. The company faces revenue declines but maintains margin improvement focus, with analyst consensus leaning toward Hold amid ongoing transformation efforts.
The outlook remains cautious with revenue weakness offset by cost discipline. Investment opportunity exists if margin gains translate to sustained profitability, but risks include persistent demand softness and high debt levels. Current valuation appears reasonable with P/S of 0.42, though negative ROE and net margins warrant careful monitoring of the brand transformation progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
